219 citations
,
January 2006 in “Drug Metabolism Reviews” DHEA affects multiple receptors and may help with metabolic issues, but its safety and effectiveness in humans are unclear.
61 citations
,
December 2001 in “Journal of Investigative Dermatology” Steroid sulfatase in hair follicles may be a target for treating hair loss.
108 citations
,
April 2004 in “Medicinal Research Reviews” Steroid sulfatase inhibitors could help treat hormone-related disorders and cancers.
5 citations
,
January 1993 in “Hormone and Metabolic Research” DHEA and DHEA-S help maintain underarm hair in older women.
7 citations
,
January 1971 in “Archives of Dermatological Research” 2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
4 citations
,
January 1989 in “Journal of Steroid Biochemistry” Women with hyperandrogenism have higher androgen levels and lower SHBG, which may contribute to conditions like excessive hair growth and early puberty.
January 2006 in “Benzina: Revista d'excepcions culturals” Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.
November 1971 in “PubMed”
April 2019 in “Journal of Investigative Dermatology” Testosterone affects androgen receptors and lipid storage in cells, while DHEA does not convert to testosterone or affect these receptors in the same way.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
Cyproterone acetate with ethynyl estradiol significantly improved acne and seborrhea in women, but was less effective for hair loss and excessive hair growth.
35 citations
,
November 1989 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Epitestosterone may act as a weak antiandrogen and can inhibit an enzyme involved in testosterone metabolism.
March 2012 in “Society for Endocrinology BES 2012” A new method was developed to analyze certain hormones and drugs in human blood efficiently.
41 citations
,
July 2001 in “PubMed” Estrogens can reduce DHT production in hair follicles, but are less effective than finasteride and progesterone.
36 citations
,
October 2009 in “Journal of Investigative Dermatology” Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.
April 2022 in “Reactions Weekly” 2 citations
,
October 1988 in “Steroids” Certain hormone treatments can increase SBP levels and help with mild body hair growth.
28 citations
,
March 1973 in “The Journal of Clinical Endocrinology & Metabolism” Altered DHEA metabolism in hair follicles may be linked to hair loss in balding men.
February 2025 in “East African Scholars Journal of Medical Sciences” Higher testosterone and DHEA-S levels may be linked to male pattern baldness.
December 1998 in “Acta Crystallographica Section C-crystal Structure Communications” A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.
41 citations
,
March 2016 in “The Journal of Clinical Endocrinology & Metabolism” In STSD patients, the body compensates for low androgen levels by increasing another enzyme's activity.
39 citations
,
August 2004 in “International journal of gynaecology and obstetrics” Finasteride and CPA-EE2 equally reduce hirsutism, but affect hormone levels differently.
111 citations
,
August 2002 in “Journal of Medicinal Chemistry” New compounds were made that block an enzyme linked to breast cancer better than existing treatments.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
11 citations
,
October 1986 in “International Journal of Gynecology & Obstetrics” The contraceptive reduced hair growth and altered hormone levels in hirsute women.
April 2019 in “Journal of the Endocrine Society” A rare adrenal tumor in a woman only made DHEA-S, causing hair thinning, and was removed, fixing the hormone level.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
May 2022 in “Current Enzyme Inhibition” Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.